This site is no longer being updated. Data are accurate as of 2 Dec 2022.

ImmunityBio Inc: hAd5-Covid-19

ImmunityBio Inc: hAd5-Covid-19

Vaccine Type: Non Replicating Viral Vector

About Trial Phases

Phase 1: 5 Trials

NCT04591717
United States of America
NCT04710303
South Africa
NCT04732468
United States of America
NCT04843722
United States of America
NCT04845191
United States of America

Phase 2: 2 Trials

NCT04843722
United States of America
NCT04845191
United States of America

Phase 3: 0 Trials

There are no trials for this phase.

Approvals

This vaccine is not yet approved.

Registered Trials

NCT04843722
Phase 1/2
United States of America
Total Enrollment: 540
Official Trial Registration:
- NCT04843722(Opens in new tab/window)
NCT04845191
Phase 1/2
United States of America
Total Enrollment: 540
Official Trial Registration:
- NCT04845191(Opens in new tab/window)
NCT04591717
Phase 1
United States of America
Total Enrollment: 35
Official Trial Registration:
- NCT04591717(Opens in new tab/window)
NCT04710303
Phase 1
South Africa
Total Enrollment: 35
Official Trial Registration:
- NCT04710303(Opens in new tab/window)
NCT04732468
Phase 1
United States of America
Total Enrollment: 65
Official Trial Registration:
- NCT04732468(Opens in new tab/window)

© 2023 VIPER Group COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form